Tel Aviv-Based Matricelf Reports Positive Safety Results for Spinal Cord Implant
Matricelf Ltd., a Tel Aviv-based regenerative medicine company, has completed a Good Laboratory Practice (GLP) safety study for its ...
Ang artikulong ito ay awtomatikong isinalin mula sa orihinal na ulat sa Ingles ng IsraelFM. Basahin ang orihinal na artikulo sa Ingles
Jerusalem, 17 June, 2026 (TPS-IL) — Matricelf Ltd., a Tel Aviv-based regenerative medicine company, has completed a Good Laboratory Practice (GLP) safety study for its engineered neural tissue implant for spinal cord injury, moving it closer to a first-in-human clinical trial.
The study, conducted on 248 animals over a 39-week period, found no treatment-related toxicity, tumor formation, or implant migration. The results support the safety profile of the personalized therapy, which uses patient-derived cells and biomaterials.